162. Curr Breast Cancer Rep. 2018;10(2):35-40. doi: 10.1007/s12609-018-0274-y. Epub2018 Apr 16.Immunotherapy in Breast Cancer: the New Frontier.Hu ZI(1), McArthur HL(2).Author information: (1)1Mount Sinai Health System, Icahn School of Medicine, New York, NY USA.(2)2Department of Medicine, Breast Oncology, Samuel Oschin Comprehensive CancerInstitute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, 1S35, Los Angeles, CA 90048 USA.Purpose of review: This review summarizes current immunotherapies in breastcancer, with an emphasis on immune checkpoint inhibitors and vaccines.Recent findings: Combination immunotherapy with checkpoint inhibitors andcytotoxic therapies have shown promising results. Active clinical trials areongoing in both early stage and metastatic settings for triple negative, HER2+,and hormone-positive breast cancer patients.Summary: Ongoing challenges remain in defining biomarkers that predict responseto immunotherapy, determining the optimal combination immunotherapies, andenhancing the immunogenicity of breast cancer subtypes.DOI: 10.1007/s12609-018-0274-y PMCID: PMC5970253PMID: 29881518 